Wyndham Hotels & Resorts (WH) Q2 2024 earnings summary

Executive summary

• Achieved strong Q2 2024 results with 4% global room growth, 6% Adjusted EBITDA growth, and 12% Adjusted EPS growth year-over-year, driven by robust development activity and disciplined cost management.

• Opened over 18,000 rooms globally, including the first ECHO Suites Extended Stay, with 33% more development deals signed in the U.S. and a record pipeline of 245,000 rooms, marking 16 consecutive quarters of growth.

• Returned over $250 million to shareholders year-to-date, including $162 million in Q2 through share repurchases and dividends, and nearly 45% of market cap since 2019.

• Net income for Q2 2024 was $86 million, up 23% year-over-year, with diluted EPS of $1.07, reflecting higher revenues and lower expenses.

• Wyndham Connect, an AI-driven guest engagement platform, was rolled out to nearly 2,000 hotels, enhancing guest experience and ancillary revenue.

Financial highlights

• Q2 2024 fee-related and other revenues were $366 million, up $8 million year-over-year, with net revenues at $367 million, led by higher royalties, franchise fees, and ancillary revenues.

• Adjusted EBITDA reached $178 million, up 13% year-over-year, with margin improving to 85%.

• Adjusted diluted EPS was $1.13, up 22% year-over-year, aided by share repurchases and a lower tax rate.

• Adjusted free cash flow was $69 million in Q2 and $171 million year-to-date, with a 54%–60% conversion rate from Adjusted EBITDA.

• Net income for the first half of 2024 was $102 million, a 26% decrease from the prior year, mainly due to higher transaction-related and impairment expenses.

Outlook and guidance

• 2024 RevPAR growth outlook updated to be essentially flat year-over-year, with fee-related and other revenues expected at $1.41–$1.43 billion.

• Net room growth guidance unchanged at 3%–4%; Adjusted EBITDA guidance remains $690–$700 million.

• Adjusted diluted EPS outlook raised to $4.20–$4.32, reflecting share repurchases.

• Multi-year outlook reaffirmed: Adjusted EBITDA CAGR of 7%–10% and potential Adjusted EPS CAGR in the mid-teens through 2026.

• Guidance excludes expenses related to the defense of a hostile takeover attempt.